<DOC>
	<DOCNO>NCT00006478</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build immune response kill cancer cell . Vaccine therapy may effective treatment non-Hodgkin 's lymphoma . PURPOSE : Phase II trial study effectiveness vaccine therapy follow chemotherapy peripheral stem cell transplantation treat patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Following Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine humoral cellular immune response patient follicular non-Hodgkin 's lymphoma treat autologous lymphoma-derived idiotype vaccine keyhole limpet hemocyanin plus sargramostim ( GM-CSF ) . - Determine safety toxicity regimen patient post-transplant setting . - Determine change quantitative bcl-2 blood bone marrow patient various time series idiotype vaccine . OUTLINE : Vaccinations begin day 100 6 month hematopoietic stem cell transplantation . Patients receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously ( SC ) day 1 . Sargramostim ( GM-CSF ) SC administer day 1-4 . Treatment repeat every 4 week 4 dos , follow 12 week later fifth final dose . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven grade I , II , III follicular nonHodgkin 's lymphoma fail induction therapy Previously receive 2 highdose chemotherapy hematopoietic stem cell transplantation Minimal disease state day 100 6 month posttransplantation Lymph nod small 2 centimeter ( cm ) Less 20 % bone marrow involvement lymphoma Uncertain complete remission , define great 75 % reduction size pretransplantation mass represent active disease Tissue sample safely accessible biopsy , needle aspiration , phlebotomy Must adequate circulate lymphoma cell PATIENT CHARACTERISTICS : Age : Over 19 Performance status : Karnofsky great 70 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute neutrophil count great 1,000/mm^3* CD4+ count great 200/microliter* NOTE : *No restriction study vaccine administer 6 month transplantation Hepatic : Bilirubin le 2.0 mg/dL ( unless due lymphomatous involvement ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) less 2 time normal ( unless due lymphomatous involvement ) Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>